Anti-PADI4 / PAD4 antibody [4H5] (ab128086)

Overview

• Product nameAnti-PADI4 / PAD4 antibody [4H5]See all PADI4 / PAD4 primary antibodies ...
• Description
  Mouse monoclonal [4H5] to PADI4 / PAD4
• Tested applicationsWB, IHC-P, Flow Cyt, ICC/IF more details
• Species reactivity
  Reacts with: Human
  
• Immunogen

  Recombinant full length protein, corresponding to amino acids 1-663 of Human PADI4 / PAD4 produced in HEK293T cells (NP_036519).

• Positive controlHEK293T cells transfected with PADI4 / PAD4 , Human breast, Carcinoma of Human lung, Adenocarcinoma of Human ovary, Human pancreas, Adenocarcinoma of Human endometrium, Human prostate, Carcinoma of Human prostate, Carcinoma of Human bladder and Human lymphoma tissues, COS7 cells transiently transfected by pCMV6-ENTRY PADI4 / PAD4 , Hela and Jurkat cells
• General notesDilute in PBS (pH7.3) before use.

Properties

• FormLiquid
• Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles.
• Storage bufferpH: 7.30
  Preservative: 0.02% Sodium azide
  Constituents: 48% PBS, 50% Glycerol, 1% BSA
• Concentration information loading...
• PurityProtein A purified
• Clonality Monoclonal
• Clone number4H5
• IsotypeIgG2a
• Research Areas
  • Metabolism
  • Pathways and Processes
  • Metabolic signaling pathways
  • Amino acid metabolism

  • Signal Transduction
  • Metabolism
  • Amino Acids

  • Epigenetics and Nuclear Signaling
  • Chromatin Modifying Enzymes
  • Arginine Deiminases

  • Epigenetics and Nuclear Signaling
  • Chromatin Modifying Enzymes
  • Methylation
  • Arginine Deimination

Applications

Target

• FunctionCatalyzes the citrullination/deimination of arginine residues of proteins. Citrullinates histone H3 at 'Arg-8' and/or 'Arg-17' and histone H4 at 'Arg-3', which prevents their methylation by CARM1 and HRMT1L2/PRMT1 and represses transcription. Citrullinates EP300/P300 at 'Arg-2142', which favors its interaction with NCOA2/GRIP1.
• Tissue specificityExpressed in eosinophils and neutrophils, not expressed in peripheral monocytes or lymphocytes.
• Involvement in diseaseGenetic variations in PADI4 are a cause of susceptibility to rheumatoid arthritis (RA) [MIM:180300]. It is a systemic inflammatory disease with autoimmune features and a complex genetic component. It primarily affects the joints and is characterized by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Note=Could have an important role in the pathogenesis of rheumatoid arthritis by increasing citrullination of proteins in rheumatoid arthritis synovial tissues, leading, in a cytokine-rich milieu, to a break in tolerance to citrullinated peptides processed and presented in the appropriate HLA context.
• Sequence similaritiesBelongs to the protein arginine deiminase family.
• Cellular localizationCytoplasm. Nucleus. Cytoplasmic granule. Cytoplasmic granules of eosinophils and neutrophils.

Target information above from: UniProt accession Q9UM07 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010) .

Information by UniProt
• Database links
  • Entrez Gene: 23569 Human
  • Entrez Gene: 23569 Human
  • Entrez Gene: 23569 Human
  • GenBank: NP_036519 Human
  • Omim: 605347 Human
  • SwissProt: Q5VTZ8 Human
  • SwissProt: Q9UM07 Human
  • SwissProt: Q9UM07 Human

  • SwissProt: Q9UM07 Human
  • Unigene: 522969 Human

  see all

• Alternative names
  EC 3.5.3.15 antibodyHL 60 PAD antibodyHL-60 PAD antibody

  PAD 4 antibodyPAD antibodyPADI 4 antibodyPADI 5 antibodyPADI H protein antibodyPadi4 antibodyPADI4_HUMAN antibodyPADI5 antibodyPDI 4 antibodyPDI 5 antibodyPDI4 antibodyPDI5 antibodyPeptidyl arginine deiminase type IV antibodyPeptidyl arginine deiminase type V antibodyPeptidylarginine deiminase IV antibodyProtein arginine deiminase antibodyProtein arginine deiminase type 4 antibodyProtein arginine deiminase type IV antibodyProtein-arginine deiminase type IV antibodyProtein-arginine deiminase type-4 antibody

  see all

Anti-PADI4 / PAD4 antibody [4H5] images

• 

  Western blot - Anti-PADI4 / PAD4 antibody [4H5] (ab128086)
  All lanes : Anti-PADI4 / PAD4 antibody [4H5] (ab128086) at 1/2000 dilution
  
  Lane 1 : HEK293T cells transfected with pCMV6-ENTRY control cDNA
  Lane 2 : HEK293T cells transfected with pCMV6-ENTRY PADI4 / PAD4 cDNA
  
  Lysates/proteins at 5 µg per lane.
  
  
  Predicted band size : 74 kDa
  
• 

  Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PADI4 / PAD4 antibody [4H5] (ab128086)
  ab128086, at a dilution of 1/150, staining PADI4 / PAD4 in paraffin-embedded Human breast tissue by Immunohistochemistry.
• 

  Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PADI antibody [4H5] (ab128086)
  ab128086, at a dilution of 1/150, staining PADI4 / PAD4 in paraffin-embedded carcinoma of Human lung tissue by Immunohistochemistry.
• 

  Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PADI antibody [4H5] (ab128086)
  ab128086, at a dilution of 1/150, staining PADI4 / PAD4 in paraffin-embedded Adenocarcinoma of Human ovary tissue by Immunohistochemistry.
• 

  Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PADI antibody [4H5] (ab128086)
  ab128086, at a dilution of 1/150, staining PADI4 / PAD4 in paraffin-embedded Human pancreas tissue by Immunohistochemistry.
• 

  Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PADI antibody [4H5] (ab128086)
  ab128086, at a dilution of 1/150, staining PADI4 / PAD4 in paraffin-embedded Adenocarcinoma of Human endometrium tissue by Immunohistochemistry.
• 

  Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PADI antibody [4H5] (ab128086)
  ab128086, at a dilution of 1/150, staining PADI4 / PAD4 in paraffin-embedded Human prostate tissue by Immunohistochemistry.
• 

  Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PADI antibody [4H5] (ab128086)
  ab128086, at a dilution of 1/150, staining PADI4 / PAD4 in paraffin-embedded Carcinoma of Human prostate tissue by Immunohistochemistry.
• 

  Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PADI antibody [4H5] (ab128086)
  ab128086, at a dilution of 1/150, staining PADI4 / PAD4 in paraffin-embedded Carcinoma of Human bladder tissue by Immunohistochemistry.
• 

  Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PADI antibody [4H5] (ab128086)
  ab128086, at a dilution of 1/150, staining PADI4 / PAD4 in paraffin-embedded Human lymphoma tissue by Immunohistochemistry.
• 

  Immunocytochemistry/ Immunofluorescence - Anti-PADI antibody [4H5] (ab128086)
  ab128086, at a dilution of 1/100, staining COS7 cells transiently transfected by pCMV6-ENTRY PADI4 / PAD4 by Immunofluorescence.
• 

  Flow Cytometry - Anti-PADI antibody [4H5] (ab128086)
  ab128086, at a dilution of 1/100, staining PADI4 / PAD4 in HeLa cells (Red), compared to a nonspecific negative control antibody (Blue), analysed by Flow cytometric.
• 

  Flow Cytometry - Anti-PADI antibody [4H5] (ab128086)
  ab128086, at a dilution of 1/100, staining PADI4 / PAD4 in Jurkat cells (Red), compared to a nonspecific negative control antibody (Blue), analysed by Flow cytometric.